adlitterio66339

About adlitterio66339

This author has not yet filled in any details.
So far adlitterio66339 has created 715 blog entries.

28 09, 2022

Silvia Chiesa et al., Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma

adlitterio663392022-10-13T15:41:55+02:00

15 09, 2022

Eleonora Nardi et al., A study on the placenta in stillbirth: an evaluation of molecular alterations through next generation sequencing

adlitterio663392022-10-13T15:47:35+02:00

8 09, 2022

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – August 2022

adlitterio663392022-09-08T14:15:04+02:00

1 09, 2022

Alessandro Dal Maso et al., EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience

adlitterio663392022-10-20T11:47:26+02:00

30 08, 2022

Valentina Grespi et al., Human neural stem cells drug product: Microsatellite instability analysis

adlitterio663392022-10-20T11:50:15+02:00

4 08, 2022

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – July 2022

adlitterio663392022-08-04T09:42:52+02:00

1 08, 2022

Pina Ziranu et al., CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors

adlitterio663392022-10-20T11:57:14+02:00

23 07, 2022

Chiara Nicolazzo et al., A Fast and Furious Liquid Biopsy Assay to Monitor Targeted Therapy Resistance

adlitterio663392022-10-14T11:22:50+02:00

18 07, 2022

Monthly focus on regulatory status of new targeted therapies in oncology – June 2022

adlitterio663392022-07-18T11:28:45+02:00

15 07, 2022

Diatech will attend the Jahrestagung Congress 7-10 October 2022, Vienna
Diatech will attend the Jahrestagung Congress 7-10 October 2022, Vienna

Events, News

Diatech will attend the Jahrestagung Congress 7-10 October 2022, Vienna

adlitterio663392022-07-15T16:14:18+02:00

Previous 141516 Next